Results 51 to 60 of about 378,238 (343)

Efficacy and Tolerability of Topotecan/Cyclophosphamide/Dinutuximab in Relapsed and Refractory High‐Risk Neuroblastoma: A Multi‐Institutional Retrospective Study

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Purpose Chemoimmunotherapy with irinotecan, temozolomide, and dinutuximab (I/T/DIN) has emerged as first‐line therapy for relapsed/refractory (r/r) high‐risk neuroblastoma (HRNB) in North America. Topotecan and cyclophosphamide (T/C) are often used in combination with dinutuximab in the setting of lack of response, progression, or incomplete ...
Benjamin J. Lerman, Madeleine King, Rajen Mody, Sara‐Jane Onyeama, Araz Marachelian, Thomas Cash, Sara M. Federico, Meaghan Granger, Ami V. Desai, Suzanne Shusterman, Jennifer H. Foster, Elizabeth Sokol, Chelsee Greer, Keri Streby, Holly J. Meany, Kieuhoa T. Vo, Margaret E. Macy, Rochelle Bagatell   +17 more
wiley   +1 more source

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. [PDF]

, 2004
BACKGROUND: An open-label study indicated that selective depletion of B cells with the use of rituximab led to sustained clinical improvements for patients with rheumatoid arthritis. To confirm these observations, we conducted a randomized, double-blind,
Close, DR, Edwards, JCW, Emery, P, Filipowicz-Sosnowska, A, Shaw, T, Stevens, RM, Szczepanski, L, Szechinski, J   +7 more
core   +1 more source

Extracorporeal shockwave against inflammation mediated by GPR120 receptor in cyclophosphamide-induced rat cystitis model

Molecular Medicine, 2018
Background We tested the hypothesis that extracorporeal shockwave treatment (ESWT) can abolish inflammation and restore urothelial barrier integrity in acute interstitial cystitis by upregulating the fatty acid receptor GPR120.
Yi-Ling Chen, Yuan-Ping Lin, Cheuk-Kwan Sun, Tien-Hung Huang, Hon-Kan Yip, Yen-Ta Chen   +5 more
doaj   +1 more source

The Efficacy and Safety of Bevacizumab/Irinotecan/Temozolomide (BIT) for Relapsed/Refractory Neuroblastoma: The UK Children's Cancer and Leukaemia Group Experience

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Patients with high‐risk neuroblastoma who either are refractory to induction chemotherapy or relapse following multi‐modal treatment have a dismal prognosis. Based on data from the BEACON trial, since 2021 the UK national guidelines recommend bevacizumab, irinotecan, and temozolomide (BIT) for patients with relapsed/refractory ...
Thomas J. Jackson, Menna Shamma, Upeka Senanayake, Shaimaa Sahmoud, Kathleen Duffin, Victoria Howard, David King, Ayesha Fathani, Blanche Lumb, Andrei Pobischan, Irum Latif Memon, Monzir Ahmed, Rhian Thomas, Gerard Millen, Yasmeen Alomari, Sucheta Vaidya, Lynley V. Marshall, Sally L. George, Ramya Ramanujachar, Juliet Gray, Paola Angelini   +20 more
wiley   +1 more source

Paravasation with cyclophosphamide - Case report of tissue necrosis in a patient with primary breast cancer [PDF]

, 2007
Background: Paravasation is a rare but severe complication of treatment with cytotoxic agents. Some anticancer drugs are considered to be of high toxicity (vesicant), some are merely irritant, and some are regarded as nearly non-toxic to healthy tissue ...
Adami NP, Bertelli G, Boyle DM, Dorr RT, Goolsby TV, Jordan K, Reich B, Tsavaris NB   +7 more
core   +1 more source

Mechanisms of Graft-versus-Host Disease Prevention by Post-transplantation Cyclophosphamide: An Evolving Understanding

Frontiers in Immunology, 2019
Post-transplantation cyclophosphamide (PTCy) has been highly successful at preventing severe acute and chronic graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT). The clinical application of this approach was based
N. S. Nunes, C. Kanakry
semanticscholar   +1 more source

Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5 [PDF]

, 2017
Background The purpose of this study was to determine the cardiac safety and clinical activity of trastuzumab and bevacizumab with docetaxel after epirubicin with cyclophosphamide (EC) in patients with HER2-positive locally advanced breast cancer (LABC ...
Ansari, Bilal, Buyse, Marc E., Conlin, Alison K., Geyer, Charles E., Jr., Gross, Howard M., Jacobs, Samuel A., Keogh, George P., Lord, Raymond S., Mamounas, Eleftherios P., Mauquoi, Celine, Patocskai, Erica J., Polikoff, Jonathan A., Rastogi, Priya, Robidoux, André, Smith, John W., Stella, Philip J., Swain, Sandra M., Wolmark, Norman   +17 more
core   +2 more sources

A PRSZT Registry Analysis of Prognostic Factors Influencing Survival and Relapse Rates After Second Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Acute Lymphoblastic Leukemia

Pediatric Blood &Cancer, EarlyView.
ABSTRACT A second allogeneic (allo‐)hematopoietic stem cell transplantation (HSCT2) is a potential curative option for pediatric patients with acute lymphoblastic leukemia (ALL) following relapse after first allogeneic transplantation (HSCT1), but its efficacy is limited by high relapse rates and transplant‐related toxicity in highly pretreated ...
Ava Momm, Imme Haubitz, Rita Beier, Martin Zimmermann, Andrej Lissat, Peter Bader, Matthias Eyrich, Jan‐Henning Klusmann, Matthias Wölfl, Paul‐Gerhardt Schlegel, Verena Wiegering   +10 more
wiley   +1 more source

Treatment responses to antiangiogenetic therapy and chemotherapy in nonsecreting paraganglioma (PGL4) of urinary bladder with SDHB mutation: a case report [PDF]

, 2018
Paraganglioma (PGL) is a rare neuroendocrine tumor. Currently, the malignancy is defined as the presence of metastatic spread at presentation or during follow-up.
Aschelter, Am, Capriotti, G, Cerquetti, L, Lardo, P, Marchetti, P, Matarazzo, I, Nardone, Mr, Petrangeli, E, Schiavi, F, Stigliano, A, Toscano, V   +10 more
core   +1 more source

Acute Hyponatremia Complicated with Seizure after Adjuvant Chemotherapy with Cyclophosphamide and Epirubicin in a Breast Cancer Patient

Journal of Cancer Research and Practice, 2015
Cyclophosphamide is a widely-used alkylating agent with cytotoxic effects, as well as an immunosuppressive agent. In the past, life-threatening hyponatremia had been reported as a rare complication induced by both high-dose and low-dose cyclophosphamide.
Yun-Chu Lin, Dwan-Ying Chang
doaj   +1 more source